Scope & Methodology
This structured feed aggregates all identified material regulatory updates, consultations, proposed legislation, major enforcement actions, and official guidance on Artificial Intelligence released by key global regulators and other trusted sources, strictly within the timeframe of January 22, 2026 – February 25, 2026.
Each entry is mapped by geography, regulatory authority, sector, and risk domain, with source links, and summaries.
Table of Contents
United States & Canada
FDA (Food and Drug Administration) [US]
Title: Digital Health Devices TEMPO Pilot Program Launch
Citation/Identifier: FDA official, February 3, 2026
Regulator: Food and Drug Administration (FDA)
Jurisdiction/Region: United States
Status: Program Launch (final; ongoing pilot) [Assumed, pending further agency details]
Domain/Risk Area: Digital Health, Artificial Intelligence (Clinical Decision Support, Device Innovation)
Key Obligation Summary: The FDA launched the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot, focusing on innovative digital health devices. Some devices may be powered by AI/ML, with the program emphasizing real-world outcomes and streamlined regulatory engagement. The pilot specifically aims to gather evidence and feedback on regulatory pathways for novel technologies in clinical settings.
Source Link: FDA Digital Health Center of Excellence
Canada & Germany (International Initiative)
Title: Joint Declaration and Launch of Sovereign Technology Alliance
Citation/Identifier: February 14, 2026
Regulator: Governments of Canada and Germany
Jurisdiction/Region: International (Canada, Germany)
Status: Agreement Signed/Initiative Launch (final)
Domain/Risk Area: Secure AI Infrastructure, Standards, Research Commercialization
Key Obligation Summary: Canada and Germany have formalized collaboration to secure compute resources, safe system design, and standards development in AI research and commercialization. They will focus on technical safeguards, alignment of operational standards, and coordinated investments to foster responsible and secure AI.
European Union
EDPB/EDPS (European Data Protection Board and Supervisor)
Title: EDPB-EDPS Joint Opinion 1/2026 on the Digital Omnibus Proposal
Citation/Identifier: EDPB-EDPS Joint Opinion 1/2026, February 10, 2026 (published February 11, 2026)
Regulator: European Data Protection Board & European Data Protection Supervisor
Jurisdiction/Region: European Union (EU)
Status: Formal Regulatory Opinion (non-binding consultation/advice)
Domain/Risk Area: Data Protection, AI Training, GDPR Reform
Key Obligation Summary: This opinion critiques the Commission’s Digital Omnibus proposal for narrowing the definition of personal data, weakening protections in AI and pseudonymization contexts, and reducing procedural safeguards concerning access and transparency rights. The joint opinion supports potentially using legitimate interest as a basis for AI data use under the GDPR, but calls for clarity and procedural safeguards (e.g., objection rights, robust transparency). Further, the EDPB and EDPS recommend EDPB be given oversight for breach notifications and DPIA lists/templates.
EDPB – Global AI Imagery Statement
Title: EDPB Supports Global Statement on AI-Generated Imagery and Privacy
Citation/Identifier: EDPB/Global Privacy Assembly joint statement, February 23, 2026
Regulator: European Data Protection Board (EDPB)
Jurisdiction/Region: Global (with EU leadership)
Status: Policy Statement/Declaration
Domain/Risk Area: Data Privacy, AI-Generated Content (Synthetic Media, Deepfakes)
Key Obligation Summary: Calls for organizations deploying image/video-generating AI to implement strong transparency practices, easily accessible reporting/removal tools, proactive engagement with regulators, and specific child protections (such as against exploitation or bullying via deepfakes or nonconsensual imagery).
EMA (European Medicines Agency)
Title: EMA CHMP Work Plan 2026 Adopted — AI in Medicines Life Cycle
Citation/Identifier: CHMP Work Plan 2026, adopted Jan 29, 2026 (published Feb 2, 2026)
Regulator: European Medicines Agency (EMA)
Jurisdiction/Region: EU/EEA
Status: Final Work Plan (operative)
Domain/Risk Area: Medicines Regulation, AI-Driven Research/Development
Key Obligation Summary: Establishes a 2026 agenda for AI-focused regulatory pilots, workforce literacy campaigns, and “knowledge mining” workshops to support oversight of AI/ML throughout the medicinal product lifecycle, referencing the joint FDA-EMA principles for good AI practice.
United Kingdom
DCMS/Ofcom (Department for Digital, Culture, Media and Sport and Office of Communications)
Title: Amendments to Crime and Policing Bill—Extending Online Safety Act Duties to AI Chatbots
Citation/Identifier: UK Government announcement, February 16, 2026
Regulator: UK Government
Jurisdiction/Region: United Kingdom
Status: Proposed Legislation/Amendment (Parliamentary process)
Domain/Risk Area: Online Safety, Child Protection, AI-Generated Content
Key Obligation Summary: The proposed amendments close a regulatory loophole by extending existing Online Safety Act duties (e.g., illegal content risk assessments, rapid removals) to AI chatbot providers, with fines up to 10% of global turnover and a core focus on addressing AI-generated harms to children.
Source Link: Government takes action to keep children safe online
